AIM:To compare the safety and efficacy of conbercept intravitreal injection and half-dose photodynamic therapy(PDT)in treating chronic central serous chorioretinopathy(CSC).METHODS:This study was retrospective.Thirty-...AIM:To compare the safety and efficacy of conbercept intravitreal injection and half-dose photodynamic therapy(PDT)in treating chronic central serous chorioretinopathy(CSC).METHODS:This study was retrospective.Thirty-seven patients(37 eyes)with chronic CSC received conbercept injections while 57 patients(57 eyes)were treated with half-dose PDT.All subjects were followed in 6mo.Outcome measures included change in best-corrected visual acuity(BCVA),central macular thickness(CMT),subfoveal choroidal thickness(SFCT),and resolution of subretinal fluid(SRF).RESULTS:There was no adverse event observed in either treatment group.At the 6-month follow-up,26 eyes(70.3%)in the conbercept group and 54 eyes(94.7%)in the half-dose PDT group(P<0.05)reached full resolution of SRF.The mean logarithm of the minimum angle of resolution(log MAR)BCVA significantly improved(P<0.001)in both treatment groups with better outcome at early phase in the half-dose PDT group(2 wk,1,and 2 mo,P<0.05).All subjects experienced significant CMT improvement(P<0.001)with no statistical difference between the two groups(P>0.05).The SFCT also improved in all subjects(P<0.001)with better outcome in the half-dose PDT group(P<0.05).CONCLUSION:Both intravitreal conbercept and halfdose PDT are safe to use in treating chronic CSC.By 6mo,both treatment groups are efficacious in improving BCVA,reducing CMT and SFCT,and resolving SRF in eyes with chronic CSC.Half-dose PDT may show better outcome at initial phase of treatment in chronic CSC.Longer follow-up period is necessary to study for long-term effect and safety.展开更多
A case series was used to evaluate the efficacy of halffluence photodynamic therapy（PDT） for chronic central serous chorioretinopathy（CSCR）. Patients were treated with standard-dose verteporfin and half-fluence PD...A case series was used to evaluate the efficacy of halffluence photodynamic therapy（PDT） for chronic central serous chorioretinopathy（CSCR）. Patients were treated with standard-dose verteporfin and half-fluence PDT. Totally 13 eyes from 11 patients were included. The mean patient age was 52.0 y. There was a mean reduction in central retinal thickness of 107.0 microns. Totally 7/13 eyes（53.8%） achieved resolution of subretinal fluid（SRF） on optical coherence tomography（OCT） scan after 1 treatment with PDT. Four eyes had further treatment with PDT; of these 1 eye achieved resolution of SRF. Seven of the 13 eyes（53.8%） achieved an improvement of more than 5 ETDRS letters. One patient experienced acute macula oedema 1 d post PDT treatment. These results support the hypothesis that half-fluence PDT can have a positive effect in chronic CSCR for a gain in visual acuity and reduction in sub-retinal fluid. Acute macula oedema is a rare but potential adverse effect of half-fluence PDT.展开更多
Purpose: To study the safety and efficacy of 1/3-dose verteporfin photodynamic therapy (PDT) for subacute central serous chorioretinopathy (CSC). Methods: In this case series, 59 eyes (59 patients) diagnosed with suba...Purpose: To study the safety and efficacy of 1/3-dose verteporfin photodynamic therapy (PDT) for subacute central serous chorioretinopathy (CSC). Methods: In this case series, 59 eyes (59 patients) diagnosed with subacute CSC in Shenyang the 4th hospital from January 2014 to December 2015 were treated with 1/3-dose verteporfin PDT and followed up for at least 1 year. The symptoms and the diagnosed history were more than 3 months but shorter than 6 months. The central foveal thickness (CFT), neuroretinal thickness (NRT), height of subfoveal retinal fluid (SRF), and subfoveal choroidal thickness (SCT) were observed at baseline and after treated at 1, 2, 3, 6 and 12 months with EDI-OCT, Best-corrected visual acuity ( BCVA) was also studied at the same time. Results: After 1, 2, 3 and 6 months of 1/3-dose verteporfin PDT treatment, the BCVA improved significantly (P 0.05). The height of SRF changed significantly. There was no retinal pigment epithelium atrophy and choroidal neovascularization (CNV) in all cases after more than 12 months follow-up. Conclusion: Treatment of 1/3 dose verteporfin PDT could safely and effectively reduce expansion of choroidal vessel and choroidal choriocapillary, promoting absorbance of subretinal fluid for subacute CSC. 1/3-dose verteporfin PDT may be an alternative method to treat the subacute CSC.展开更多
Purpose:Subthreshold micropulse laser(SML)and photodynamic therapy(PDT)are among the most effective therapeutic modalities applied to central serous chorioretinopathy(CSCR).This study aimed to evaluate the ef-ficacy a...Purpose:Subthreshold micropulse laser(SML)and photodynamic therapy(PDT)are among the most effective therapeutic modalities applied to central serous chorioretinopathy(CSCR).This study aimed to evaluate the ef-ficacy and durability of PDT in CSCR cases unresponsive to at least two SML treatments.Methods:The study included 26 consecutive eyes of 24 patients(21 males and three females)with chronic CSCR.In all cases,a lack of reduction in subretinal fluid(SRF)levels was noted after at least two consecutive SML sessions.The parameters of best corrected visual acuity(BCVA)and spectral domain optical coherence tomog-raphy(SD-OCT)were evaluated at baseline and 1,3 and 12 months post-PDT.Results:The mean duration of symptoms in the group was 53.81±39.48 months,the mean age of the patients was 49.26±12.91 years,and the mean subfoveal choroidal thickness(SFCT)was 572.11±116.21 mm.Complete resorption of SRF was observed in 21 out of 26 eyes(80.77%)at 1 month and sustained in 18 cases(69.23%)at 12 months.At 12 months,in the sustained group,BCVA improved significantly from 0.39±0.18 to 0.19±0.2 logMAR(P=0.01),central subfoveal thickness(CST)reduced from 316.44±75.83 mm to 197.67±22.99 mm(P<0.0001),and SFCT reduced from 579.28 mm to 446.78 mm(P<0.0001).Conclusions:PDT provides the opportunity for the successful treatment of CSCR unresponsive to SML treatment.Improvements are possible even in cases with a long duration of symptoms and significant alterations in retinal morphology.Thus,PDT should be considered for patients with prominently increased choroidal thickness.展开更多
基金Supported by Wenzhou Municipal Science and Technology Bureau(No.Y20180728)Wenzhou Municipal Science and Technology Bureau(No.Y20190635)Wenzhou Municipal Science and Technology Bureau(No.2019Y0592)。
文摘AIM:To compare the safety and efficacy of conbercept intravitreal injection and half-dose photodynamic therapy(PDT)in treating chronic central serous chorioretinopathy(CSC).METHODS:This study was retrospective.Thirty-seven patients(37 eyes)with chronic CSC received conbercept injections while 57 patients(57 eyes)were treated with half-dose PDT.All subjects were followed in 6mo.Outcome measures included change in best-corrected visual acuity(BCVA),central macular thickness(CMT),subfoveal choroidal thickness(SFCT),and resolution of subretinal fluid(SRF).RESULTS:There was no adverse event observed in either treatment group.At the 6-month follow-up,26 eyes(70.3%)in the conbercept group and 54 eyes(94.7%)in the half-dose PDT group(P<0.05)reached full resolution of SRF.The mean logarithm of the minimum angle of resolution(log MAR)BCVA significantly improved(P<0.001)in both treatment groups with better outcome at early phase in the half-dose PDT group(2 wk,1,and 2 mo,P<0.05).All subjects experienced significant CMT improvement(P<0.001)with no statistical difference between the two groups(P>0.05).The SFCT also improved in all subjects(P<0.001)with better outcome in the half-dose PDT group(P<0.05).CONCLUSION:Both intravitreal conbercept and halfdose PDT are safe to use in treating chronic CSC.By 6mo,both treatment groups are efficacious in improving BCVA,reducing CMT and SFCT,and resolving SRF in eyes with chronic CSC.Half-dose PDT may show better outcome at initial phase of treatment in chronic CSC.Longer follow-up period is necessary to study for long-term effect and safety.
文摘A case series was used to evaluate the efficacy of halffluence photodynamic therapy（PDT） for chronic central serous chorioretinopathy（CSCR）. Patients were treated with standard-dose verteporfin and half-fluence PDT. Totally 13 eyes from 11 patients were included. The mean patient age was 52.0 y. There was a mean reduction in central retinal thickness of 107.0 microns. Totally 7/13 eyes（53.8%） achieved resolution of subretinal fluid（SRF） on optical coherence tomography（OCT） scan after 1 treatment with PDT. Four eyes had further treatment with PDT; of these 1 eye achieved resolution of SRF. Seven of the 13 eyes（53.8%） achieved an improvement of more than 5 ETDRS letters. One patient experienced acute macula oedema 1 d post PDT treatment. These results support the hypothesis that half-fluence PDT can have a positive effect in chronic CSCR for a gain in visual acuity and reduction in sub-retinal fluid. Acute macula oedema is a rare but potential adverse effect of half-fluence PDT.
文摘Purpose: To study the safety and efficacy of 1/3-dose verteporfin photodynamic therapy (PDT) for subacute central serous chorioretinopathy (CSC). Methods: In this case series, 59 eyes (59 patients) diagnosed with subacute CSC in Shenyang the 4th hospital from January 2014 to December 2015 were treated with 1/3-dose verteporfin PDT and followed up for at least 1 year. The symptoms and the diagnosed history were more than 3 months but shorter than 6 months. The central foveal thickness (CFT), neuroretinal thickness (NRT), height of subfoveal retinal fluid (SRF), and subfoveal choroidal thickness (SCT) were observed at baseline and after treated at 1, 2, 3, 6 and 12 months with EDI-OCT, Best-corrected visual acuity ( BCVA) was also studied at the same time. Results: After 1, 2, 3 and 6 months of 1/3-dose verteporfin PDT treatment, the BCVA improved significantly (P 0.05). The height of SRF changed significantly. There was no retinal pigment epithelium atrophy and choroidal neovascularization (CNV) in all cases after more than 12 months follow-up. Conclusion: Treatment of 1/3 dose verteporfin PDT could safely and effectively reduce expansion of choroidal vessel and choroidal choriocapillary, promoting absorbance of subretinal fluid for subacute CSC. 1/3-dose verteporfin PDT may be an alternative method to treat the subacute CSC.
基金approved by the local bioethics committee of Okrę-gowa Izba Lekarska w Gdansku(approval no.KB-35/23)on August 16,2023 and conducted according to the guidelines of the Declaration of Helsinki.
文摘Purpose:Subthreshold micropulse laser(SML)and photodynamic therapy(PDT)are among the most effective therapeutic modalities applied to central serous chorioretinopathy(CSCR).This study aimed to evaluate the ef-ficacy and durability of PDT in CSCR cases unresponsive to at least two SML treatments.Methods:The study included 26 consecutive eyes of 24 patients(21 males and three females)with chronic CSCR.In all cases,a lack of reduction in subretinal fluid(SRF)levels was noted after at least two consecutive SML sessions.The parameters of best corrected visual acuity(BCVA)and spectral domain optical coherence tomog-raphy(SD-OCT)were evaluated at baseline and 1,3 and 12 months post-PDT.Results:The mean duration of symptoms in the group was 53.81±39.48 months,the mean age of the patients was 49.26±12.91 years,and the mean subfoveal choroidal thickness(SFCT)was 572.11±116.21 mm.Complete resorption of SRF was observed in 21 out of 26 eyes(80.77%)at 1 month and sustained in 18 cases(69.23%)at 12 months.At 12 months,in the sustained group,BCVA improved significantly from 0.39±0.18 to 0.19±0.2 logMAR(P=0.01),central subfoveal thickness(CST)reduced from 316.44±75.83 mm to 197.67±22.99 mm(P<0.0001),and SFCT reduced from 579.28 mm to 446.78 mm(P<0.0001).Conclusions:PDT provides the opportunity for the successful treatment of CSCR unresponsive to SML treatment.Improvements are possible even in cases with a long duration of symptoms and significant alterations in retinal morphology.Thus,PDT should be considered for patients with prominently increased choroidal thickness.
文摘目的观察中药联合半剂量维替泊芬光动力疗法(photodynamic therapy,PDT)治疗慢性中心性浆液性脉络膜视网膜病变(central serous chororetinopathy,CSC)的效果。方法对27例36眼慢性CSC患者,行半剂量维替泊芬PDT治疗,术后根据中医辨证施治原则配合中药汤剂治疗,随访6~12个月,以最佳矫正视力(best corrected visual acuity,BCVA)、视网膜下液隆起最高点高度(the height of highest point of subretinal fluid,HPSF)作为疗效指标,观察该法有效率及复发率。结果治疗后3个月、6个月及末次随访时BCVA提高,与治疗前相比差异有统计学意义。治疗后1个月内视网膜下液吸收明显。末次随访时,显效22眼(61.11%),有效11眼(30.56%),总有效率91.76%。随访过程中1眼复发,经再次中药联合半量PDT治疗后好转。随访期间36眼未见不良反应。结论中药联合半剂量维替泊芬光动力疗法治疗慢性CSC安全有效,有效降低复发率。
